The Company reported 72% of the Company’s common stock outstanding as of the July 14, 2019 record date adopted the merger agreement and approximately 73% of the Company’s outstanding common stock as of the June 14, 2019 record date was present in person or represented by proxy at the Special Meeting. Of the shares voted, approximately 99% voted in favor of adopting the merger proposal.
The U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) approved an additional vial size (10 mL) for NOCITA® (bupivacaine liposome injectable suspension). NOCITA is currently available in a 20 mL vial size and Aratana continues to anticipate commercial availability of the NOCITA 10 mL vial by fall 2019.
The Company announced voting results for the four proposals considered and voted upon by its stockholders at its Annual Meeting on June 6, 2019. The Company reported 44,510,117 shares of common stock present in person or represented by proxy at the Annual Meeting, which represents approximately 91% of the Company’s outstanding common stock as of the April 10, 2019 record date.
The Company announced its first quarter 2019 financial results and recent business highlights.